論文・出版
2014年
ネオアジュバント化学療法後の再発リスクが高いホルモン受容体陽性HER2陰性原発性乳癌患者を対象としたサイクリン依存性キナーゼ（CDK）4/6阻害薬palbociclib（PD-0332991）を評価する第III相試験「PENLOPE試験」
岩田 広治
Cancer Board 乳癌. 2014 Dec; 7(2).
ホルモン陽性HER2陰性進行再発乳癌に対する、ホルモン療法による維持療法を利用したベバシズマブ＋パクリタキセル療法の治療最適化研究 JBCRG-M04（BOOSTER）
佐治重衡、戸井雅和
Cancer Board 乳癌. 2014 Dec; 7(2).
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
Norikazu Masuda, Kenji Higaki, Toshimi Takano, Nobuki Matsunami, Takashi Morimoto, Shoichiro Ohtani, Makiko Mizutani, Takeshi Miyamoto, Katsumasa Kuroi, Shinji Ohno, Satoshi Morita, Masakazu Toi
Cancer Chemotherapy and Pharmacology. 2014 Aug; 74(2): 229-38.
https://doi.org/10.1007/s00280-014-2492-y
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)
Masahiro Takada, Hiroshi Ishiguro, Shigenori Nagai, Shoichiro Ohtani, Hidetaka Kawabata, Yasuhiro Yanagita, Yasuo Hozumi, Chikako Shimizu, Shintaro Takao, Nobuaki Sato, Yoshimasa Kosaka, Yasuaki Sagara, Hiroji Iwata, Shinji Ohno, Katumasa Kuroi, Norikazu Masuda, Hiroyasu Yamashiro, Masahiro Sugimoto, Masahide Kondo, Yoichi Naito, Hironobu Sasano, Takashi Inamoto, Satoshi Morita & Masakazu Toi on behalf of the JBCRG-C03 Collaborative Group
Breast Cancer Research and Treatment. 2014 May; 145(1): 143-53.
https://doi.org/10.1007/s10549-014-2907-9